Frailty is a state of high vulnerability for adverse health outcomes ([@CIT0001]). It is highly prevalent in the older population and is associated with increased risk of hospitalization, institutionalization, and mortality ([@CIT0001]). Studies of potential frailty mechanisms and interventions to prevent or delay frailty are limited by the logistical and ethical issues of undertaking studies in a population that is highly dependent, potentially vulnerable, and extremely heterogeneous ([@CIT0004],[@CIT0005]).

The two most common ways of assessing frailty clinically are the frailty index (FI) and the frailty phenotype assessment ([@CIT0006],[@CIT0007]). The FI measures the accumulated health deficits in a patient ([@CIT0008],[@CIT0009]). Health deficits include symptoms, comorbidities, abnormal laboratory results, self-reported functional declines, or problems with activities of daily living ([@CIT0009],[@CIT0010]). A FI score is determined by summing the number of health-related deficits a person displays and dividing by the maximum number of possible deficits, to give a continuous variable between 0 and 1, whereby a larger number indicates a person is more frail ([@CIT0007],[@CIT0009]). The frailty phenotype assesses a person as frail based on decreased grip strength, walking speed, activity, endurance, and unintentional weight loss. A person is classified as either prefrail or frail based on their performance in these variables ([@CIT0006]). The assessment of frailty with each of these clinical tools is associated with adverse outcomes including mortality ([@CIT0011],[@CIT0012]).

Recently, there has been a focus on developing preclinical models of frailty in naturally aging mice based on these clinical assessment tools ([@CIT0013],[@CIT0014]). Parks and colleagues developed a mouse FI based on activity levels, hemodynamic measures, body composition, and metabolic status ([@CIT0015]). This was associated with age-related adverse cardiac outcomes, but included invasive and time consuming assessments ([@CIT0015]). Whitehead and colleagues continued this work and developed a 31-item mouse clinical FI based on clinically apparent health deficits ([@CIT0016]). They showed that the FI increased with age at a similar rate to that seen in human studies. The mouse clinical FI has been used to assess frailty interventions ([@CIT0017]) and the effect of frailty on outcomes ([@CIT0018],[@CIT0019]). Liu and colleagues developed a mouse frailty phenotype assessment based on a mouse's performance in four functional assessments ([@CIT0020]). This assessment has been used to assess an exercise intervention on frailty ([@CIT0021]). However, the time consuming nature of the functional assessments and the need for specialized equipment may limit its use in aging and interventional studies. Each of these mouse frailty assessments could be adapted for use in other mouse strains as well as other species ([@CIT0014]).

Rats, in particular Fischer 344 rats, are a commonly used model for aging studies ([@CIT0022]). However, as of yet, there is no tool for assessing frailty in rats. The aim of the current study was to develop a rat clinical FI in Fischer 344 rats based on the mouse clinical FI ([@CIT0016]). We also aimed to validate the tool by looking at the association of the rat clinical FI scores with mortality.

Methods {#s1}
=======

Animals {#s2}
-------

Male Fischer 344 rats purchased from Harlan Laboratories (Maine) were aged from middle age (13 months, *n* = 41) into old age (21 months) in a longitudinal study. A second cohort of young rats were aged from 6 months (*n* = 12) to 9 months, to serve as young adult comparators. Rats were fed ad libitum and housed individually on a 12-hour light/dark cycle. All experiments were approved by the Dalhousie University Committee on Laboratory Animals and performed in accordance with guidelines published by the Canadian Council on Animal Care.

Food was weighed twice weekly to assess changes in food intake. Biweekly measurements were summed and divided by 7 to calculate daily food intake. The day of death for a rat was determined as the day it was found dead or determined to be moribund by a veterinarian and euthanized. A terminal FI was assessed for each rat on the day of euthanasia, if possible.

Development of a 27-Item Clinical FI for Rats {#s3}
---------------------------------------------

A 27-item FI was developed based upon the mouse clinical FI ([@CIT0016]). The index included assessment of health deficits across the integument, musculoskeletal system, ocular/nasal systems, digestive/urogenital systems, respiratory system as well as assessment of discomfort, body weight, temperature, and food intake. Clinical signs/deficits were selected through a review of the literature on age-related changes in the F344 rat and through consultations with a veterinarian ([Table 1](#T1){ref-type="table"}). Young rats were observed in comparison to older rats to refine assessment techniques.

###### 

Clinical Signs of Deterioration in Aging Fischer 344 rats

  System/variable           Description                                                                                                            Reference
  ------------------------- ---------------------------------------------------------------------------------------------------------------------- -----------
  Alopecia                  Acquired hair loss due to inflammation, endocrine disorder, or idiopathic disease.                                     \(41\)
  Skin lesions/dermatitis   Excessive scratching, self-mutilation, or skin conditions leading to open sores on the body.                           (32,42)
  Coat condition            Ungroomed appearance: fur appears ruffled and matted.                                                                  (31,32)
  Tumours                   Presence of neoplastic growths.                                                                                        (31,42)
  Distended abdomen         Asymmetric/enlarged abdomen. May be due to neoplastic growths, organ enlargement or peritoneal fluid accumulation.     (31,43)
  Hunched posture           Presence of hunched posture (head down, feet together); reduced mobility.                                              (32,41)
  Body condition            Visual signs of emaciation or obesity. Based on the amount of flesh covering the vertebral column and dorsal pelvis.   \(25\)
  Gait disorders            Abnormal locomotion: slow movement, lack of coordination, stumbling, falling, or limping.                              (32,44)
  Tremor                    Involuntary shaking at rest.                                                                                           (45,46)
  Hearing loss              Impaired acoustic startle reflex; associated with loss of hearing sensitivity.                                         \(43\)
  Cataracts                 Opaque spot in the center of the eye; clouding of the lens.                                                            (43,44)
  Chromodacryorrhea         Porphyrin staining around the eyes/nose.                                                                               \(31\)
  Exophthalmos              Abnormal protrusion of the eye.                                                                                        \(47\)
  Microphthalmos            Abnormally small eye. Sunken in appearance.                                                                            \(48\)
  Corneal opacity           Cornea appears white or clouded.                                                                                       (41,43)
  Head tilt                 Abnormal/asymmetric head position associated with a central nervous system disturbance.                                (31,43)
  Malocclusion              Abnormal occlusion due to uneven or overgrown incisors.                                                                \(31\)
  Diarrhea                  Increased frequency and decreased consistency of bowel movements. Fecal smearing in cage.                              (31,43)
  Jaundice                  Yellowing of the feet, nose, ears and tail associated with accumulation of bilirubin.                                  \(43\)
  Penile/vaginal prolapse   Tissue protruding from the penis or vagina.                                                                            \(43\)
  Rectal prolapse           Tissue protruding from the rectum.                                                                                     \(43\)
  Breathing rate/depth      Bradypnea, tachypnea, dyspnea, or snuffling.                                                                           \(31\)
  Piloerection              Fur standing on end                                                                                                    \(32\)
  Unusual sounds            Acute vocalization in response to touch.                                                                               \(32\)
  Body weight               Increase or decrease in body weight                                                                                    (25,44)
  Food intake               Decrease in daily food intake                                                                                          \(25\)
  Body temperature          Increase or decrease in body temperature.                                                                              \(49\)

To complete the clinical FI, rats were moved to an assessment room in the animal care facility and allowed 5 minutes to acclimatize to their new surroundings. Animals were then briefly observed in their home cage prior to undergoing examination for clinical signs of deterioration as described in [Table 1](#T1){ref-type="table"}. Details of the assessment methods for each item of the FI are described in Supplementary Table 1. As outlined in ([@CIT0016]), each deficit was scored as follows: 0 if there was no sign of a deficit, 0.5 if there was a mild deficit, and 1 if there was a severe deficit. [Table 2](#T2){ref-type="table"} shows the Rat Frailty Assessment Form developed for this study, based on the mouse FI published by Whitehead and colleagues ([@CIT0016]) and refined by Feridooni and colleagues ([@CIT0023]). Deficits in body weight (g), daily food intake (g), and body surface temperature (°C) were scored based on the number of standard deviations from mean reference values calculated for young adult rats (6 months) in the current study. Reference values (mean ± SD) calculated for daily food intake, weight, and temperature for 6 month old rats were 17.7 ± 1.6 g, 371.8 ± 30.1 g, and 26.3 ± 0.4 °C, respectively. A score of 0 was given if the deficit was less than 1 SD from the reference mean, a score of 0.5 was given for 1--2 SDs difference, and a score of 1 was given for greater than 2 SDs difference. Frailty assessments were completed at 6 and 9 months for the young rats. For 36 of the old rats, frailty assessments were completed at 13, 17, and 21 months, provided the mouse survived to the time point. For the remaining 5 old rats, frailty was only evaluated at 21 months.

###### 

27-Item Index to Assess Frailty in Fischer 344 Rats

  -------------------------------------------------------- ---------------------------------------------------------------------------- ------------------ --- --------------------------------------------------
  Rat \#:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_                Date of Birth:\_\_\_\_\_\_\_\_\_\_\_\_\_                                                            
  Body Weight (g):\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_     Body Surface Temperature (°C):\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_                          
  Daily food intake (g):\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_   Sex:  F  M                                                                                          
  Rating: 0 = absent 0.5 = mild 1 = severe                                                                                                                     
  Integument                                               Comments:                                                                                           
   1. Alopecia                                             0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   2. Dermatitis                                           0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   3. Coat condition                                       0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Physical/Musculoskeletal                                                                                                                                     
   4. Tumours                                              0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   5. Distended abdomen                                    0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   6. Hunched posture                                      0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   7. Body condition score                                 0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   8. Gait disorder                                        0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   9. Tremor                                               0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Vestibulocochlear/Auditory                                                                                                                                   
   10. Hearing loss                                        0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Ocular/Nasal                                                                                                                                                 
   11. Cataracts                                           0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   12. Chromodacryorrhea/porphyrin                         0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   13. Exophthalmos                                        0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   14. Microphthalmos                                      0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   15. Corneal opacity                                     0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Neurological                                                                                                                                                 
   16. Head tilt                                           0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Digestive/Urogenital                                                                                                                                         
   17. Malocclusion                                        0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   18. Diarrhea                                            0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   19. Jaundice                                            0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   20. Penile/vaginal prolapse                             0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   21. Rectal prolapse                                     0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Respiratory                                                                                                                                                  
   22. Breathing rate/depth                                0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Pain/Discomfort                                                                                                                                              
   23. Piloerection                                        0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
   24. Unusual sounds                                      0                                                                            0.5                1   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Other                                                                                                                                                        
   25. Body weight score                                                                                                                \_\_\_\_\_\_\_\_       
   26. Temperature score                                                                                                                \_\_\_\_\_\_\_\_       
   27. Food intake score                                                                                                                \_\_\_\_\_\_\_\_       
    TOTAL SCORE =\_\_\_\_\_\_\_\_                          TOTAL SCORE/MAX SCORE =\_\_\_\_\_\_\_\_                                                             
  -------------------------------------------------------- ---------------------------------------------------------------------------- ------------------ --- --------------------------------------------------
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Statistics {#s4}
----------

Data are presented as mean ± standard error of mean unless otherwise specified. One-way repeated measures analysis of variance with Bonferroni post hoc testing was used to compare mean FI scores between age groups. To investigate the upper limit of frailty in this study, the range of FI scores, and the 99^th^ percentile FI score ([@CIT0024]) were calculated for each age group. Rat ages were normalized to a 90% mortality rate at 900 days ([@CIT0025]) to allow comparison with previously published mouse and human FI data that were normalized in the same way ([@CIT0016]). All FI scores were plotted against normalized age and fitted with an exponential growth curve (2 parameters). The natural log of all FI scores was also plotted against normalized age and fitted with a linear polynomial equation. Survival data was illustrated using a Kaplan--Meier survival curve and analyzed using the log-rank test. For the survival analysis, the continuous FI scores were dichotomously stratified by \< or \> 0.21 ([@CIT0026],[@CIT0027]). *p* values \<0.05 were considered significant. Statistical analysis was completed using SPSS 22 and Sigma Plot 11.0.

Results {#s5}
=======

Mean FI scores did not significantly change in young rats from 6 to 9 months (*p* = 0.27) but increased in old rats (*p* \< 0.0001; [Figure 1](#F1){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). Bonferroni post hoc testing showed that there was a significant difference between all 3 time points for the older rats ([Figure 1](#F1){ref-type="fig"}). The mean FI for terminal FI scores was 0.31 ± 0.02 ([Table 3](#T3){ref-type="table"}). The range of FI scores also increased with age in the older rats, as did the 99^th^ percentile FI score ([Table 3](#T3){ref-type="table"}). Supplementary Table 2 shows the scoring of the individual deficits in the FI at the different assessment time points. The proportion of rats scored 0.5 or 1 increased for each deficit over time (Supplementary Table 2).

![Mean frailty index (FI) scores for young (**A**) and old (**B**) rats at various ages. One-way repeated measures ANOVA determined a significant difference across all time points for the old rats. ANOVA, analysis of variance.](glw33901){#F1}

###### 

Summary Statistics for Frailty Index Scores for Younger and Older Rats

                                  Younger rats   Older rats                                              
  ------------------------------- -------------- ------------- ------------- ------------- ------------- -------------
  *N*                             12             12            36            33            23            18
  Mean FI score                   0.03 ± 0.01    0.04 ± 0.01   0.06 ± 0.00   0.13 ± 0.01   0.21 ± 0.01   0.31 ± 0.02
  FI score range                  0.00--0.11     0.00--0.11    0.02--0.11    0.04--0.30    0.11--0.35    0.19--0.40
  99^th^ Percentile of FI score   0.11           0.11          0.11          0.28          0.34          0.40

Abbreviation: FI, frailty index.

Rat ages were normalized to a 90% mortality rate at 900 days ([@CIT0025]) to allow comparison with previously published mouse and human FI data that were normalized in the same way ([@CIT0016]). [Figure 2A](#F2){ref-type="fig"} shows all of the individual rat frailty scores plotted against normalized age, fitted with an exponential curve (*r*^2^ = 0.64, *p* \< 0.0001, *n* = 116). [Figure 2B](#F2){ref-type="fig"} shows the natural logarithm of FI score plotted as a function of normalized rat age. The slope of the line, which represents the rate of deficit accumulation ([@CIT0016],[@CIT0028]) was 0.045 (*p* \< 0.0001).

![Individual FI scores for older rats fitted with an exponential curve (*r*^2^ = 0.64, *p* \< 0.0001, *n* = 116) (**A**). The natural logarithm of FI versus time fitted with a straight line (slope = 0.045, *p* \< 0.0001, *n* = 116) (**B**). All rat ages are normalized to the 90% mortality rate at 900 days.](glw33902){#F2}

Of the 41 older rats, 18 (44%) died before 21 months of age, and of these, 3 died before 17 months of age. [Figure 3](#F3){ref-type="fig"} shows that a high FI score is associated with an increased probability of mortality when assessed with Kaplan--Meier curves in rats with FI scores completed at 17 months (panel A) and 21 months (panel B). Log-rank tests showed that for frailty assessments completed at both 17 months (*n* = 33 rats, 8 excluded for missing FI scores or mortality before this time point) and terminally/at 21 months (*n* = 41 rats), there was a significant difference between the survival curves for FI \>0.21 and FI \<0.21 (*p* \< 0.0001 and *p* = 0.007, respectively). For both time points a greater proportion of rats with higher FI scores, compared to lower scores, died before 21 months. Of the rats assessed for frailty at 17 months, 2 rats had FI scores \>0.21 and both rats (100%) died before 21 months of age, while 31 rats had FI scores \<0.21 and 13 (41.9%) of these died before 21 months ([Figure 3A](#F3){ref-type="fig"}). Of the rats assessed for frailty terminally or at 21 months, 24 rats had FI scores \>0.21 and 15 (62.5%) died before 21 months, while 17 mice had FI scores \<0.21 and 3 (17.6%) of these died before 21 months ([Figure 3B](#F3){ref-type="fig"}).

![Kaplan--Meier curves for 21 month survival probability stratified by frailty index (\< or \> 0.21), for mice assessed for FI at age 17 months (**A**) or mice assessed for FI terminally (**B**). Log-rank analysis showed a significant difference between the curves for both time points (**A**, *p* \< 0.0001; **B**, *p* \< 0.01). **A**, *n* = 33 (8 excluded for missing FI scores or mortality before this time point); **B**, *n* = 41.](glw33903){#F3}

Discussion {#s6}
==========

This study is the first to develop a frailty assessment tool for use in rats. We successfully developed a rat clinical FI based on deficit accumulation across a range of systems. We then used this tool to assess frailty in rats, and found a significant increase in mean FI scores as the rats aged. We also further validated the FI by looking at the association with mortality and found that high FI scores increased the risk of death.

An exponential increase in mean FI scores with age, and an increase in the variability of FI scores with age has been seen in FI studies of humans, mice ([@CIT0016],[@CIT0023]) and now rats. In the current study, the rate of deficit accumulation as determined from a graph of the natural log of FI plotted against normalized age was 0.045. A previous study found the rate of accumulation to be 0.038 in mice and 0.034 in humans ([@CIT0016]). This may suggest that rats accumulate deficits at a higher rate than mice or humans but would require further studies. Interestingly, in the current study, our maximum FI score was 0.40, which is close to the maximum FI scores seen in previous clinical FI studies in mice ([@CIT0016],[@CIT0023]). Also of interest, clinical studies have clearly shown that there is a submaximal limit to frailty in humans ([@CIT0029]) and animal model data strongly suggest that such a limit is also present in mice ([@CIT0016],[@CIT0023]) and now in rats (our data). Furthermore, we saw an association between high FI score and mortality risk in the current study. The association of FI and mortality has not yet been explored in mice but has been clearly shown in clinical studies ([@CIT0002]). The quantification of the accumulation of health deficits as a model of frailty appears to be conserved across species. This provides evidence for the value of the rat FI tool, but also for the FI as a concept.

It will be interesting for further studies to explore the FI in other mouse and rat strains, as well as other species ([@CIT0014]). As the mouse clinical FI was adapted in the current study to be suitable for Fischer 344 rats, each of these FIs could be adapted for use in other strains or species with adjustment or replacement of the deficit items for strain- or species-specific deficits. For example, as the Fischer 344 are an albino rat strain, some deficits such as chromodacryorrhea may not be as clearly identifiable in nonalbino rat strains such as Long--Evans rats. Additionally, some deficits that were not applicable for Fischer 344 rats may be applicable for other strains or species. For example, vision loss was used as a deficit in the mouse clinical FI, but light-induced retinal degeneration is universal among albino rats exposed to fluorescent or incandescent light ([@CIT0030]).

There are several other health-related deficits that could be incorporated into the rat clinical FI for future studies. Whisker loss ([@CIT0031]), splayed posture ([@CIT0032]), increased nail length ([@CIT0032]), and decreased muscle tone ([@CIT0032],[@CIT0033]) are also seen in aging rats and could easily be assessed. There has been some criticism of the mouse clinical FI for the lack of assessment of cognitive deficits ([@CIT0034]). It may be possible to include hopping or placing reflex assessment ([@CIT0033],[@CIT0035],[@CIT0036]) as measures of cognitive deficits in the rat clinical FI.

There are some limitations to the current study, and more studies should be undertaken to further validate this tool. The rats in the current study were only aged until 21 months, and as the 50% mortality age of Fischer 344 rats is 26 months ([@CIT0025]), or 23 months for singly housed rats ([@CIT0037]) it would be interesting to look at the changes in frailty, and the associations with mortality in even older animals. The current study also only used one assessor for the FI, which ensures the data is consistent across individual rats and time points. However, it would be interesting in future studies to look at the inter-rater reliability of the rat clinical FI, as has been done for the mouse clinical FI ([@CIT0023],[@CIT0038]). The current study looks at the relationship between rat FI and mortality. Although this is an important outcome, it would also be interesting to look at the association of the rat FI with other adverse outcomes such as functional decline. It would also be possible to develop a rat phenotype assessment, based on the mouse phenotype assessment ([@CIT0020]) and look at the association between frailty in the rat measured with these two tools. Finally, the current study used a cut point of 0.21 for the FI for the Kaplan--Meier analysis, as has been used in previous clinical studies ([@CIT0026],[@CIT0027]). Although cut points are frequently used for clinical FI studies, the cut points for use in preclinical studies may still require optimization. As the rate of deficit accumulation appeared to be higher in rats, this may mean that a lower cut point may be appropriate when dichotomising rat FI data.

As with the mouse models of frailty, the rat clinical FI will have great value in preclinical studies of frailty mechanisms, interventions, and outcomes. Preclinical models of frailty are an increasingly important area as evidenced by several recent reviews ([@CIT0014],[@CIT0034],[@CIT0039],[@CIT0040]). The mouse clinical FI has been used to show that dietary and pharmaceutical interventions can attenuate frailty ([@CIT0017]), as well as in studies looking at frailty as a geriatric outcome ([@CIT0018]). Given that rats are commonly preferred for behavioral studies, and are a commonly used aging model ([@CIT0022]), the rat clinical FI could be an important tool for use in aging studies.

We have developed a convenient and relevant rat clinical FI assessment tool to assess frailty in aging Fischer 344 rats. The rat clinical FI is an important contribution to the growing area of preclinical models of frailty.

Supplementary Material {#s7}
======================

Supplementary data are available at *The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences* online.
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